Hjem › Plexiformt neurofibrom › Maryland
Kliniske studier for Plexiformt neurofibrom i Maryland
6 studier for Plexiformt neurofibrom søker deltakere på steder i Maryland.
Offisiell studietekst (engelsk)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 5 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT02544022Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 3 til 120 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06222203Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1
Alder 3 til 35 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT02390752A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
- Johns Hopkins Hospital, Baltimore
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06541847A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
- National Institutes of Health Clinical Center, Bethesda
Rekrutterer
Alder 1 til 120 · Alle kjønn · Oppdatert 9. jun. 2026 · NCT06507748Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
- Johns Hopkins University, Baltimore
- National Cancer Institute/ National Institutes of Health, Bethesda
RekruttererFase 2
Alder 1 til 8 · Alle kjønn · Oppdatert 29. mai 2026 · NCT06188741Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.